Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder
NCT02371980 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder
- Lead sponsor
- Takeda
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 10, 2015
- Completion date
- April 25, 2019
- Enrollment
- 1,106 (actual)
- Sites
- 79
Conditions
As the registry lists them; a condition with its own page is linked.